Transgenomic Posts Narrowed Q3 Loss, Expects Profitability in 02 | GenomeWeb

NEW YORK, Oct. 31 - Transgenomic reported a third-quarter net loss of 8 cents per share on top of revenues of $10.3 million, a 64 percent increase over the same period last year, and said it intends to become profitable by the end of 2002.

“The strength of our balance sheet, with $47 million in cash and investments, with no debt, gives us the resources needed to execute our plan to achieve profitability by the end of 2002,” CEO Collin D'Silva said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.